- Home
- PROK vs NPCT Comparison
PROK vs NPCT Comparison
Compare PROK & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- NPCT
- Stock Information
- Founded
- PROK 2015
- NPCT 2020
- Country
- PROK United States
- NPCT United States
- Employees
- PROK N/A
- NPCT N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- NPCT Investment Managers
- Sector
- PROK Health Care
- NPCT Finance
- Exchange
- PROK Nasdaq
- NPCT Nasdaq
- Market Cap
- PROK 334.8M
- NPCT 314.9M
- IPO Year
- PROK N/A
- NPCT N/A
- Fundamental
- Price
- PROK $3.11
- NPCT $10.92
- Analyst Decision
- PROK Buy
- NPCT
- Analyst Count
- PROK 5
- NPCT 0
- Target Price
- PROK $6.25
- NPCT N/A
- AVG Volume (30 Days)
- PROK 2.5M
- NPCT 107.1K
- Earning Date
- PROK 11-11-2025
- NPCT 01-01-0001
- Dividend Yield
- PROK N/A
- NPCT 9.82%
- EPS Growth
- PROK N/A
- NPCT N/A
- EPS
- PROK N/A
- NPCT N/A
- Revenue
- PROK $527,000.00
- NPCT N/A
- Revenue This Year
- PROK $338.06
- NPCT N/A
- Revenue Next Year
- PROK N/A
- NPCT N/A
- P/E Ratio
- PROK N/A
- NPCT N/A
- Revenue Growth
- PROK N/A
- NPCT N/A
- 52 Week Low
- PROK $0.46
- NPCT $8.58
- 52 Week High
- PROK $7.13
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- PROK 54.93
- NPCT 44.77
- Support Level
- PROK $2.34
- NPCT $10.82
- Resistance Level
- PROK $3.02
- NPCT $10.98
- Average True Range (ATR)
- PROK 0.17
- NPCT 0.13
- MACD
- PROK 0.03
- NPCT -0.00
- Stochastic Oscillator
- PROK 65.59
- NPCT 47.61
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.